The Diagnostic Value Of Constitutive B7-H3Molecule Expression In Primary Hepatic Carcinoma And Change After Interventional Therapy

Objective:To compare the expression of B7-H3in primary hepatocellular carcinoma patients,hepatitis B patients, healthy controls, and change before and after transcathter arterialchemoembolization(TACE）therapy, explore the biological action of B7-H3in tumorimmune escape.Materials and methods:1.20PHC patients were enrolled in the study. All patients were confirmed by thehistopathology or according to the clinical diagnostic criteria.16patients with hepatitisB and16healthy controls as control group. All of the20patients with primary hepaticcarcinoma received transcathter arterial chemoembolization (TACE).2. All of the20patients with primary hepatic carcinoma were drew vein blood2~3days before and4~5days after TACE, hepatitis B patients and healthy controls were drewblood during the same period as liver cancer patients. And PHC patients afterTACE treated with liver-protecting treatment and symptomatic treatment. Testing theconstitutive B7-H3molecule expression in primary hepatic carcinoma patients, hepatitisB patients and healthy controls by ELISA.3. Statistical analysis: Applying SPSS17.0statistic software, adopting t-test，chi-square test analysis are applicated in the study. The statistical difference is significantwhen the P value is <0.05. According to the expression of the constitutive B7-H3moleculein primary hepatocellular carcinoma patients, hepatitis B patients and healthy controls,creating ROC curves, analysis statistical difference.Results:1. The sensitivity of the constitutive B7-H3molecule in diagnosis and screening tests in PHC patientsAccording to the expression of the constitutive B7-H3molecule in primaryhepatocellular carcinoma patients, hepatitis B patients and healthy controls, we createdROC curves. The area under the curve are0.669, P=0.027,95%CI (0.541,0.197). Whenthe density of B7-H3reaches32.3534ng/ml in peripheral serum, its sensitivity is95%and specificity is54%in the diagnosis of PHC.2. The expression of the constitutive B7-H3molecule in PHC patients peripheralserumThe expression of the constitutive B7-H3molecule in primary hepatocellularcarcinoma patients, hepatitis B patients and healthy controls are respectively48.221±14.210ng/ml,19.771±19.063ng/ml,27.212±9.972ng/ml. The expression of the constitutiveB7-H3molecule in live cancer group is higher than in hepatitis B patients group, withstatistically significant difference (P<0.001). The expression of the constitutive B7-H3molecule in live cancer group is higher than in healthy controls group, with statisticallysignificant difference (P<0.001). The expression of the constitutive B7-H3molecule inhealthy controls group is higher than in hepatitis B patients group, with indifferencestatistics (P=0.180).3. The change of the expression of the constitutive B7-H3molecule before and afterTACE in liver cancer patients peripheral serumThe density of the constitutive B7-H3molecule is48.221±14.210ng/ml in liver cancerpatients group, and55.450±4.867ng/ml after TACE. The expression of the constitutiveB7-H3molecule in live cancer group is lower after TACE, with statistically significantdifference (P=0.042).4. The relation between the expression of the constitutive B7-H3molecule andclinical parameters in PHC patients.The density of B7-H3is35.258±13.496ng/ml in the liver cancer patients of Ⅰ-Ⅱ,and51.460±12.781ng/ml of Ⅲ-Ⅳ, with statistically significant difference (P=0.037). Theexpression of the constitutive B7-H3molecule in live cancer group is nostatistically significant with tumor size, pathologic type, AFP, lymph nodes metastasis,Child-Pugh, and ECOG.5. The related factors of higher expression of B7-H3after TACE in primary hepaticcarcinoma patients. The higher expression of B7-H3after TACE was related to AFP, with statisticallysignificant difference (P=0.037). The higher expression of B7-H3is no statisticallysignificant with tumor size, pathologic type, lymph nodes metastasis, TNM, Child-Pugh,and ECOG.Conclusions:1. The expression of the constitutive B7-H3molecule has potential clinicalapplication value as screening tests indicator in the primary hepatic carcinoma patients.These results preliminarily showed that when the density of B7-H3reaches32.3534ng/ml in peripheral serum, its sensitivity is95%and specificity is54%in the diagnosis ofPHC.2. The expression of the constitutive B7-H3molecule in live cancer group is higherthan in hepatitis B patients group, with statistically significant difference. The expressionof the constitutive B7-H3molecule in live cancer group is higher than in healthy controlsgroup, with statistically significant difference. The expression of the constitutive B7-H3molecule in healthy controls group is higher than in hepatitis B patients group, withindifference statistics.3. The expression of the constitutive B7-H3molecule in PHC patients group ishigher after TACE, with statistically significant difference.4. The density of B7-H3is lower in the primary hepatic carcinoma patients of Ⅰ-Ⅱthan patients of Ⅲ-Ⅳ, with statistically significant difference. The expression of theconstitutive B7-H3molecule in live cancer group is no statistically significant with tumorsize, pathologic type, AFP, lymph nodes metastasis, Child-Pugh, and ECOG.5. The B7-H3expression was higher after4~5days of TACE. The higher expressionwas related to AFP, with statistically significant difference. The positive expression ofB7-H3is no statistically significant with tumor size, pathologic type, lymph nodesmetastasis, TNM, Child-Pugh, and ECOG.